摘要
用１３１Ⅰ标记的抗人肝癌单克隆抗体Ｈｅｐａｍａ－１，对１５例经手术病理证实为原发性肝细胞癌的病人，在放射免疫治疗过程中，进行了放射免疫显象研究。注射治疗量的。１３１Ⅰ－Ｈｅｐａｍａ－１ＭｃＡｂ后，用单光子发射型计算机断层扫描仪（ＳＰＥＣＴ）对病人作了动态显象观察。结果１１例阳性，４例阴性，阳性显象率为７３．３％。研究表明，１３１Ⅰ－Ｈｅｐａｍａ－１ＭｃＡｂ对原发性肝癌的定位、定性诊断，以及导向治疗等，都具有一定意义，值得进一步研究。
patients with hepatoma were treated with 131Ⅰ-labeled Hepama-1 McAb.All of them had been pathologically proven to be primary hepatocellularcarcioma.11/15 patients(73.3%)were visualized during the treatments with radioimmunoimaging.These results show that 131Ⅰ-Hepama-1 McAb can be concentrated in hepatic tumor,so that it is valuable for as a guide in diagnostic localization,and therapy of hepatocellular carcinoma.
出处
《上海医科大学学报》
CSCD
1994年第2期117-119,T008,共4页
Journal of Fudan University(Medical Science)
关键词
肝肿瘤
单克隆抗体
免疫疗法
癌
hepatocellular carcinoma
radionulide immaging
antibody
monoclone
￣(131)Ⅰ label
